A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

NCT01863667 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Omarigliptin
DRUG: Glimepiride
DRUG: Omarigliptin Placebo
DRUG: Glimepiride Placebo

Sponsor

Merck Sharp & Dohme LLC